Riboxx, CNBG unite in collaboration

A research collaboration has been announced between Riboxx Pharmaceuticals GmbH and China National Biotec Group Co. Ltd. to evaluate Riboxxim, Riboxx’s TLR3 agonist, with an antigen from CNBG against an undisclosed infectious disease target

Apr 07, 2013|1 min read

Jeffrey Bouley

RADEBEUL, Germany—A research collaboration has beenannounced between Riboxx Pharmaceuticals GmbH and China National Biotec GroupCo. Ltd. (CNBG) to evaluate Riboxxim, Riboxx's TLR3 agonist, with an antigenfrom CNBG against an undisclosed infectious disease target. Under the terms ofthe collaboration, Riboxx will provide access to the compound while CNBGevaluates it in conjunction with its antigen against the disease target.

"We are delighted to initiate this collaboration with CNBG,which is one of the leading developers of vaccines against serious infectiousdiseases. Our TLR3 agonist has the potential to increase the efficacy of theantigen and provide a safe, but highly effective, immune response against thedisease," Dr. Jacques Rohayem, CEO of Riboxx, said in a press release.